 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Pharmas and Dx Partners Race to Launch the First Personalized EGFR Inhibitor for Lung Cancer
January 16, 2013
Pharmas and Dx Partners Race to Launch the First Personalized EGFR Inhibitor for Lung Cancer
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Roche Receives FDA Nod for New PGx Indication for Tarceva in Metastatic NSCLC with Companion Dx
May 15, 2013 / Pharmacogenomics Reporter - Boehringer Launches 'Let's Test' Campaign to Educate Healthcare Providers on NSCLC Biomarker Testing
October 24, 2012 / Pharmacogenomics Reporter - Largest Trial of EGFR-Mutated NSCLC Patients Promises New Personalized Treatment Option
June 6, 2012 / Pharmacogenomics Reporter - Pfizer Using Qiagen KRAS Test to Study Dacomitinib Head-to-Head Against Tarceva in NSCLC
August 17, 2011 / Pharmacogenomics Reporter - Roche Gets Positive CHMP Review for Tarceva as First-line Treatment in EGFR-mutated NSCLC
July 27, 2011 / Pharmacogenomics Reporter